Hepatitis C (HCV) treatment using interferon-α (IFN-α) and ribavirin is recommended in HIV/HCV co-infected patients to prevent liver cirrhosis and liver-related death. However, in addition to its antiviral activity, IFN is a pleiotropic cytokine able to synergistically amplify T-cell autoreactivity. Here, we report for the first time the induction of a subfulminant autoimmune hepatitis (AIH) after four months of a successful treatment of HCV-1b infection using peg-IFN and ribavirin, in a 48-year-old woman co-infected with HIV. Diagnosis was assessed according to the international AIH scoring system, including liver biopsy and confirmed by positive response to steroid challenge.
Salmon-CéronDCL, LewdenC, MorlatP.The Mortality 2000 Study Group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.J Hepatol2005; 42: 799–805.
2.
EdlinBR, CardenMR.Injection drug users: the overlooked core of the hepatitis C epidemic.Clin Infect Dis2006; 42: 673–6.
3.
SorianoV, PuotiM, SulkowskiM.Care of patients with hepatitis C and HIV co-infection.AIDS2004; 18: 1–12.
4.
CarratF, Bani-SadrF, PolS.Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.JAMA2004; 292: 2839–48.
5.
ChungRT, AndersenJ, VolberdingP.Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.N Engl J Med2004; 351: 451–9.
6.
TorrianiFJ, Rodriguez-TorresM.Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.N Engl J Med2004; 351: 438–50.
7.
ConradB.Potential mechanisms of interferon-alpha induced autoimmunity.Autoimmunity2003; 36: 519–23.
8.
AlvarezF, BergPA, BianchiFB.International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis.J Hepatol1999; 31: 929–38.
9.
FrenchM, PriceP, StoneS.Immune restoration disease after antiretroviral therapy.AIDS2004; 18: 1615–27.
10.
PellicanoR, SmedileA, PeyreS.Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.Minerva Gastroenterol Dietol2005; 51: 55–61.
11.
RaananiP, Ben-BassatI.Immune-mediated complications during interferon therapy in hematological patients.Acta Haematol2002; 107: 133–44.
12.
Garcia-BueyL, Garcia-MonzonC, RodriguezS.Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C.Gastroenterology1995; 108: 1770–7.
13.
BironC.Interferons α and β as immune regulators-A new look.Immunity2001; 14: 661–4.
14.
KamalSM, FehrJ, RoeslerB, PetersT, RasenackJW.Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.Gastroenterology2002; 123: 1070–83.
15.
HaradaK, Van de WaterJ, LeungPS.In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset.Hepatology1997; 25: 791–6.
16.
BerardiS, LodatoF, GramenziA.High incidence of allograft dysfunction in liver transplant patients treated with peg-Interferon alfa-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?Gut2007; 56: 237–42.
17.
VanderlugtCL, MillerSD.Epitope spreading in immune-mediated diseases: implications for immunotherapy.Nat Rev Immunol2002; 2: 85–95.
